2,5-Pyridinedicarboxylic acid is a bioactive and highly selective inhibitor of D-dopachrome tautomerase.
暂无分享,去创建一个
B. Sankaran | V. Bhandari | A. Parkins | G. Pantouris | Pragnya Das | Vanessa M. Rangel | Varsha M. Prahaladan | Liang Xue
[1] J. Bernhagen,et al. D‐dopachrome tautomerase in cardiovascular and inflammatory diseases—A new kid on the block or just another MIF? , 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] V. Bhandari,et al. A Cysteine Variant at an Allosteric Site Alters MIF Dynamics and Biological Function in Homo- and Heterotrimeric Assemblies , 2022, Frontiers in Molecular Biosciences.
[3] W. Quax,et al. Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells , 2022, Journal of medicinal chemistry.
[4] T. Holowka,et al. MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model. , 2021, The Journal of clinical investigation.
[5] Petra E. van der Wouden,et al. 4‐Iodopyrimidine Labeling Reveals Nuclear Translocation and Nuclease Activity for Both MIF and MIF2 , 2021, Chemistry.
[6] Devin K. Schweppe,et al. Redox-dependent Structure and Dynamics of Macrophage Migration Inhibitory Factor Reveal Sites of Latent Allostery , 2021, bioRxiv.
[7] George P. Lisi,et al. The N-terminus of MIF Regulates the Dynamic Profile of Residues Involved in CD74 Activation. , 2021, Biophysical journal.
[8] V. Bhandari,et al. A structurally preserved allosteric site in the MIF superfamily affects enzymatic activity and CD74 activation in D-dopachrome tautomerase , 2021, The Journal of biological chemistry.
[9] John Z. H. Zhang,et al. MolGpka: A Web Server for Small Molecule pKa Prediction Using a Graph-Convolutional Neural Network , 2021, J. Chem. Inf. Model..
[10] Bin Liu,et al. D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling , 2021, EBioMedicine.
[11] George P. Lisi,et al. Regulation of MIF Enzymatic Activity by an Allosteric Site at the Central Solvent Channel. , 2020, Cell chemical biology.
[12] B. Eynde,et al. Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma? , 2020, Annual Review of Cancer Biology.
[13] J. Bernhagen,et al. Differential regulation of macrophage activation by the MIF cytokine superfamily members MIF and MIF‐2 in adipose tissue during endotoxemia , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] Avner Schlessinger,et al. PyVOL: a PyMOL plugin for visualization, comparison, and volume calculation of drug-binding sites , 2019, bioRxiv.
[15] L. Leng,et al. A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity , 2019, The Journal of Biological Chemistry.
[16] F. Vincent,et al. Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis , 2018, Clinical & translational immunology.
[17] L. Leng,et al. Nanosecond Dynamics Regulate the MIF-Induced Activity of CD74. , 2018, Angewandte Chemie.
[18] R. Bucala,et al. Structural Plasticity in the C-Terminal Region of Macrophage Migration Inhibitory Factor-2 Is Associated with an Induced Fit Mechanism for a Selective Inhibitor. , 2018, Biochemistry.
[19] B. L. de Groot,et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.
[20] Botao Wang,et al. D‐dopachrome tautomerase is over‐expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth , 2016, International journal of cancer.
[21] J. Qian,et al. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1 , 2016, Science.
[22] T. Y. Cho,et al. Structural basis for decreased induction of class IB PI3‐kinases expression by MIF inhibitors , 2016, Journal of cellular and molecular medicine.
[23] L. Kenner,et al. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer , 2016, Oncotarget.
[24] A. Schetter,et al. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. , 2016, Cancer research.
[25] R. Bucala,et al. An Analysis of MIF Structural Features that Control Functional Activation of CD74. , 2015, Chemistry & biology.
[26] Berk Hess,et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .
[27] H. Tilg,et al. Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions , 2015, The Journal of Immunology.
[28] J. Bernhagen,et al. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP‐70 signaling, and lymphocyte chemotaxis , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] R. Bucala,et al. Targeting distinct tautomerase sites of D‐DT and MIF with a single molecule for inhibition of neutrophil lung recruitment , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] L. Leng,et al. The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. , 2014, The Journal of clinical investigation.
[31] H. Ball,et al. Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1 , 2014, Amino Acids.
[32] Philip R. Evans,et al. How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.
[33] R. Bucala,et al. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. , 2012, Cytokine.
[34] O. Lesur,et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF) , 2011, Proceedings of the National Academy of Sciences.
[35] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[36] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[37] Kirk W. Johnson,et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast , 2010, Proceedings of the National Academy of Sciences.
[38] J. Bernhagen,et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4 , 2009, FEBS letters.
[39] Alexander D. MacKerell,et al. CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..
[40] C. Metz,et al. Macrophage CD74 contributes to MIF-induced pulmonary inflammation , 2009, Respiratory research.
[41] L. Leng,et al. Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions. , 2009, Biochemistry.
[42] L. Leng,et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.
[43] J. Bernhagen,et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.
[44] L. Leng,et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.
[45] Oliver F. Lange,et al. Generalized correlation for biomolecular dynamics , 2005, Proteins.
[46] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[47] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[48] T. Calandra,et al. Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.
[49] L. Leng,et al. MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.
[50] Elias Lolis,et al. The Tautomerase Active Site of Macrophage Migration Inhibitory Factor Is a Potential Target for Discovery of Novel Anti-inflammatory Agents* , 2002, The Journal of Biological Chemistry.
[51] P. Gregersen,et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis , 2002, Genes and Immunity.
[52] S. Yamamoto,et al. Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. , 2001, Journal of medicinal chemistry.
[53] I. Tanaka,et al. Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. , 1999, Biochemistry.
[54] D. Wiley,et al. Structure of a trimeric domain of the MHC class II‐associated chaperonin and targeting protein Ii , 1998, The EMBO journal.
[55] I. Tanaka,et al. Molecular cloning of human D-dopachrome tautomerase cDNA: N-terminal proline is essential for enzyme activation. , 1998, Biochemical and biophysical research communications.
[56] J. Bernhagen,et al. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[57] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[58] M. Pabst,et al. Removal of endotoxin from protein solutions by phase separation using Triton X-114. , 1990, Journal of immunological methods.
[59] B. Bloom,et al. Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.
[60] P. Tilstam,et al. Elucidating the role of an immunomodulatory protein in cancer: From protein expression to functional characterization. , 2019, Methods in enzymology.
[61] Y. Al-Abed,et al. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. , 2011, Future medicinal chemistry.
[62] M. Feldmann,et al. Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis , 2007, Molecular medicine.
[63] E. Norkus,et al. Interaction of pyridine‐2,5‐dicarboxylic acid with heavy metal ions in aqueous solutions , 2005 .
[64] R. Bucala,et al. The Immunoregulatory Mediator Macrophage Migration Inhibitory Factor (MIF) Catalyzes a Tautomerization Reaction , 1996, Molecular medicine.